血清CXCL14、CTGF、IL-6水平联合检测对特发性肺间质纤维化患者预后的预测价值

摘要/Abstract

摘要： 目的探讨血清趋化因子14（CXCL14）、结缔组织生长因子（CTGF）、白介素6（IL-6）水平在不同预后患者中的表达水平,分析三者与病情程度相关性及联合检测对特发性肺间质纤维化（IPF）患者预后的预测价值。方法回顾性选取濮阳市安阳地区医院2022年6月—2023年4月收治的103例IPF患者为研究对象,依据治疗6个月后预后情况,将患者分为预后良好组（46例）、预后不良组（57例）。比较2组治疗前、治疗1个月后血清CXCL14、CTGF、IL-6水平,和2组治疗1个月后肺功能指标[肺总量（TLC）、肺活量（VC）、一秒率（FEV₁/FVC）]、高分辨率CT（HRCT）评分,分析其相关性及血清CXCL14、CTGF、IL-6水平联合检测对IPF预后的预测价值。结果治疗1个月后,预后不良组血清CXCL14、CTGF、IL-6水平、HRCT评分高于预后良好组,肺功能指标低于预后良好组,差异有统计学意义（P<0.05）;治疗1个月后血清CXCL14、CTGF、IL-6水平、HRCT评分低于治疗前,肺功能指标高于治疗前,差异有统计学意义（P<0.05）;血清CXCL14、CTGF、IL-6水平与肺功能指标呈负相关,与HRCT评分呈正相关,差异有统计学意义（P<0.05）;血清CXCL14、CTGF、IL-6水平及联合预测IPF患者预后不良的AUC为0.788、0.757、0.819、0.912,联合检测价值高于单一指标检测,差异有统计学意义（P<0.05）。结论血清CXCL14、CTGF、IL-6水平与IPF预后关系密切,三者联合检测可为临床预测IPF患者预后不良提供有效参考。

关键词: CXCL14, CTGF, IL-6, 特发性肺间质纤维化, 预后

Abstract: Objective To investigate the expression levels of serum Chemokine C-X-C motif ligand 14 (CXCL14), connective tissue growth factor (CTGF) and interleukin-6 (IL-6) inpatients with different prognosis, and to analyze the correlation between the three and the severity of the disease and the predictive value of combined detection for the prognosis of patients with idiopathic pulmonary fibrosis (IPF). Methods A total of 103 patients with IPF admitted to Puyang Anyang Prefecture Hospital hospital from June 2022 to April 2023 were selected as the research objects. The patients were divided into good prognosis group (46 cases) and poor prognosis group (57 cases) according to the prognosis after 6 months of treatment. The serum levels of CXCL14, CTGF, and IL-6 between the two groups before treatment and one month after treatment were compared, as well as the pulmonary function parameters [total lung capacity (TLC), vital capacity (VC), and the ratio of forced expiratory volume in one second to forced vital capacity (FEV1/FVC)] and high-resolution CT (HRCT) scores one month after treatment. The correlations of serum CXCL14, CTGF, and IL-6 levels with both the pulmonary function parameters and HRCT scores were analyzed, and the predictive value of combined detection of these serum markers for the prognosis of IPF was evaluated. Results After one month of treatment, the levels of serum CXCL14, CTGF, IL-6 and the HRCT score in the poor prognosis group were higher than those in the good prognosis group, and the lung function indexes were lower than those in the good prognosis group, the differences were statistically significant (P<0.05); after one month of treatment, the levels of serumCXCL14, CTGF and IL-6 and the HRCT score were lower than those before treatment, and the lung function index was higher than that before treatment, the differences were statistically significant (P<0.05); the levels of serumCXCL14, CTGF and IL-6 was negatively correlated with lung function index and positively correlated with HRCT score, and the differences were statistically significant (P<0.05); the AUC of the levels of serum CXCL14, CTGF and IL-6 and combined prediction of poor prognosis in IPF patients were 0.788, 0.757, 0.819, 0.912, and the value of combined detection was higher than that of single index detection, the differences were statistically significant (P<0.05). Conclusion The levels of serum CXCL14, CTGF and IL-6 is closely related to the prognosis of IPF, and the combined detection of the three can provide an effective reference for predicting the poor prognosis of IPF patients.

Key words: CXCL14, CTGF, IL-6, idiopathic pulmonary fibrosis, prognosis

中图分类号:

R563

李鹏飞. 血清CXCL14、CTGF、IL-6水平联合检测对特发性肺间质纤维化患者预后的预测价值[J]. 承德医学院学报, 2025, 42(6): 473-477.

LI Pengfei. Prognostic value of combined detection of serum levels of CXCL14, CTGF and IL-6 in patients with idiopathic pulmonary fibrosis[J]. Journal of Chengde Medical University, 2025, 42(6): 473-477.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: http://tougao.cdmc.edu.cn:8088/CN/

http://tougao.cdmc.edu.cn:8088/CN/Y2025/V42/I6/473

参考文献

[1] 张廷伟,涂弟纬,李洪波. 肺泡Ⅱ型上皮细胞衰老在特发性肺纤维化中的研究进展[J]. 国际呼吸杂志,2022,42(16):1263-1268.
[2] 陈炜,张念志,胡梦娟. 益气养阴活血法对特发性肺纤维化大鼠血管新生的影响[J]. 西部中医药,2023,36(9):14-18.
[3] 李佳怡,王亚菲,郝月琴,等. CXCL14、TGF-β1和CTGF水平与特发性肺纤维化的关系[J].中华肺部疾病杂志(电子版),2021,14(2):222-224.
[4] 叶俏,代华平. 特发性肺纤维化诊断和治疗中国专家共识[J]. 中华结核和呼吸杂志,2016,39(6):427-432.
[5] 熊梦清,赵杨,胡克. 特发性肺纤维化中的线粒体质量控制[J]. 临床肺科杂志,2022,27(3):445-449.
[6] 李雅亭,岳红梅,刘苗苗,等. 磷酸二酯酶4抑制剂作为特发性肺纤维化药物治疗的可能性[J]. 中国临床药理学与治疗学,2023,28(7):818-823.
[7] 张倩,张伟. 基于“阳化气阴成形”理论探讨特发性肺纤维化的中医证治[J]. 光明中医,2023,38(9):1653-1655.
[8] Chang TM, Chiang YC, Lee CW, et al.CXCL14 promotes metastasis of non-small cell lung cancer through ACKR2-depended signaling pathway[J]. Biol Sci, 2023, 19(5): 1455-1470.
[9] 魏会强,李海宁,郝秀玲,等. 特发性肺纤维化患者血清血管生成素-2、潜在转化生长因子结合蛋白2、趋化因子配体14水平与预后的关系研究[J]. 现代生物医学进展,2022,22(7):1301-1305.
[10] 张新月,陈明茜,白巧红,等. 特发性肺纤维化患者血清LTBP2、CXCL14水平变化及其与预后的关系[J]. 山东医药,2022,62(13):62-65.
[11] 孙宇,任宇,于松,等. 血清CTGF和FN1水平与良性前列腺增生患者预后的相关性分析[J]. 微创泌尿外科杂志,2023,12(6):379-384.
[12] 李宁,陈谨,何耀红,等. COPD合并肺间质纤维化患者临床特点及血清TGF-β1、CTGF、TNF-α检测意义分析[J]. 现代生物医学进展,2022,22(24):4644-4647,4626.
[13] 田玉恒. CTGF、TGF-β1水平变化与慢性阻塞性肺疾病肺功能的相关性[J]. 深圳中西医结合杂志,2021,31(4):10-12.
[14] Kurche JS, Stancil IT, Michalski JE, et al.Dysregulated Cell-Cell Communication Characterizes Pulmonary Fibrosis[J]. Cells, 2022, 11(20): 3319.
[15] 李运军,陈玉秋,何仁增,等. N-乙酰半胱氨酸雾化吸入对特发性肺纤维化患者肺泡灌洗液TGF-β1、IL-6、VEGF的影响[J]. 浙江中西医结合杂志,2021,31(3):230-233.